Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,234 matching trials from the live ClinicalTrials.gov search.
Conditions
Cardiovascular Disease
Interventions
AZD3366, Placebo, Ticagrelor, acetylsalicylic acid (ASA)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Glendale, California
Conditions
Healthy
Interventions
TT-01025-CL
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer
Interventions
AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib), AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig), AZD8205 in combination with AZD9574, AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
Duarte, California • Irvine, California • Santa Monica, California + 11 more
Conditions
Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer, Rectal Adenocarcinoma, Endometrial Cancer
Interventions
ATX-559
Drug
Lead sponsor
Accent Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Aurora, Colorado • Oklahoma City, Oklahoma • Nashville, Tennessee + 2 more
Conditions
Soft Tissue Sarcoma, Bone Sarcoma
Interventions
Cyclophosphamide, attIL2-T cells
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Escalation Study of GSK2838232 in Healthy Subjects

NCT01802918
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232, Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Healthy Participants
Interventions
BMS-986465, Placebo, Pegasys, Famotidine
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Anaheim, California • Austin, Texas
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions
VOR33, Mylotarg
Biological · Drug
Lead sponsor
Vor Biopharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
14
States / cities
La Jolla, California • Stanford, California • Miami, Florida + 10 more
Conditions
Wet Age-related Macular Degeneration
Interventions
EYP-1901
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 8 more
Conditions
Progressive Supranuclear Palsy (PSP), Healthy Participants
Interventions
[18F]ABBV-964i, [18F]ABBV-965i, Lead Candidate
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Gastrointestinal Neoplasms, Cholangiocarcinoma, Pancreatic Neoplasms
Interventions
BI 905711
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
New Haven, Connecticut • New York, New York • Houston, Texas + 1 more
Conditions
Healthy Subjects
Interventions
PF-06882961, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
CD20 Positive Non Hodgkin Lymphoma
Interventions
CPO107
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Charlotte, North Carolina
Recruiting No phase listed Observational

ViewFlex X ICE First-in-Human Study

NCT06772493
Conditions
Cardiac Arrhythmias
Interventions
ViewFlex X ICE System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Jonesboro, Arkansas • La Jolla, California • Jacksonville, Florida + 5 more
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia, Cancer, Refractory, Progression, Diffuse Large B Cell Lymphoma, Multiple Myeloma, Lymphoma, Lymphoma, Non-Hodgkin, Myeloma, Plasma-Cell, Myelomatosis, Plasma Cell Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
BMF-219
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Irvine, California • Los Angeles, California • Sacramento, California + 13 more
Conditions
Cancer, Neoplasms
Interventions
GSK2849330
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Aurora, Colorado • New York, New York • Salt Lake City, Utah
Conditions
HIV -1 Infection
Interventions
BNT351, Placebo
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • St Louis, Missouri + 1 more
Conditions
Glioblastoma
Interventions
ITI-1001
Drug
Lead sponsor
Immunomic Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Advanced Squamous Tumors
Interventions
ABBV-711, Budigalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Chicago, Illinois + 3 more
Conditions
Triple Negative Breast Neoplasms
Interventions
ladiratuzumab vedotin, Pembrolizumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more
Conditions
Solid Tumor, Adult
Interventions
DF9001, KEYTRUDA® (pembrolizumab)
Drug
Lead sponsor
Dragonfly Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Gilbert, Arizona • Phoenix, Arizona • Irvine, California + 14 more
Conditions
Solid Tumors
Interventions
Oral ONC201
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Obese, Overweight, Healthy
Interventions
LB64640, Placebo
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 70 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
Interventions
MHU650
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Huntington Beach, California • Honolulu, Hawaii • Hagerstown, Maryland + 2 more